Table 2.
Comparison of characteristics for subjects with a confirmed diagnosis of COPD (ie, post-bronchodilator FEV1/FVC <0.70) with and without bronchodilator reversibility
| Reversibility (n=60) | No reversibility (n=627) | P-value | |
|---|---|---|---|
| Sex, male | 35 (58%) | 334 (52%) | 0.452 |
| Age | 63 (10.0) | 63 (10.5) | 0.407 |
| BMI | 26 (5.7) | 26 (5.0) | 0.531 |
| Pack-years | 42 (23.5) | 40 (23.2) | 0.380 |
| Symptoms | |||
| Cough | 33 (55%) | 468 (75%) | 0.001 |
| Dyspnea | 43 (72%) | 355 (57%) | 0.024 |
| Wheezing | 16 (27%) | 167 (27%) | 0.996 |
| Sputum | 25 (42%) | 256 (41%) | 0.900 |
| Recurrent RTI | 10 (17%) | 78 (12%) | 0.349 |
| MRC | 2.2 (0.8) | 2.0 (0.8) | 0.152 |
| Spirometry | |||
| FEV1 screeninga | 1.7 (0.6) | 1.9 (0.7) | 0.014 |
| FEV1% predictedb | 58 (13.4) | 68 (19.6) | <0.001 |
Notes: Data are given as the mean (standard deviation) or number (%) of subjects; a positive reversibility test defined as ΔFEV1 >0.200 L and 12% of pre-bronchodilator FEV1 level after administration of bronchodilator
a
FEV1 at initial screening spirometry
b
FEV1 % predicted.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MRC, Medical Research Council dyspnea scale; RTI, respiratory tract infection.